Your session is about to expire
← Back to Search
Ipilimumab + DLI for Leukemia
Study Summary
This trial is testing a cancer drug to see what the highest safe dose is and what side effects it has in patients with different types of blood cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer treatment or still have side effects from treatments done more than 4 weeks ago, except for hydroxyurea.I do not have any serious illnesses that would stop me from following the study's requirements.I am not HIV-positive or not on antiretroviral therapy.I have had a donor lymphocyte infusion in the past.I agree to use birth control during and after the study as required.I haven't taken high doses of steroids for conditions other than GVHD in the last 4 weeks.I am not pregnant.I can take care of myself but might not be able to do heavy physical work.You have had allergic reactions in the past to drugs similar to Ipilimumab or other drugs being used in this study.I haven't taken any systemic treatments for GVHD in the last 4 weeks.My cancer (AML, MDS, or MPN) has returned and shows more than 5% blasts in the marrow.My cancer has spread to areas like the brain, eyes, or testes.My organs are functioning well.I have been treated with specific immune therapies before.I do not have autoimmune diseases like Crohn's, lupus, or rheumatoid arthritis, but Hashimoto's thyroiditis is okay.I do not have active, uncontrolled hepatitis B or C.My condition worsened 2 months after a closely matched stem cell transplant.I am 18 years old or older.I have received an organ transplant from another person.I have had severe graft-versus-host disease or it's currently active and needs treatment.
- Group 1: CD25/Treg-depleted DLI + Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities for enrolment in this experiment?
"This clinical trial, which was initiated on July 10th 2019 is currently seeking participants. The most recent update to the study's information occured on June 10th 2022."
How many participants have enrolled in this experimental investigation?
"Affirmative. According to clinicaltrials.gov, this experimental treatment is still enrolling patients since its initial post on July 10th 2019 and subsequent update from June 10th 2022. Only 25 individuals are required for the trial which will be hosted at two different sites."
Are there any precursory tests that have been conducted using Ipilimumab?
"Currently, there are 318 clinical trials being conducted on Ipilimumab around the world. Of those active studies, 38 have reached Phase 3 and 20362 locations across America are running these investigations with a particular focus in Pittsburgh, Pennsylvania."
Has the FDA sanctioned Ipilimumab for therapeutic use?
"Given the initial stages of this trial, there is limited evidence to support both safety and efficacy. Therefore, our team at Power awarded Ipilimumab a score of 1 on their rating scale."
In what clinical contexts is Ipilimumab typically employed?
"Ipilimumab is frequently administered to treat cutaneous melanoma and, in some cases, can be used to address conditions like complete resection, metastatic melanoma, or liver carcinoma."
Share this study with friends
Copy Link
Messenger